{
    "id": "f98d7d80-ecf4-4cb8-9a9b-5ffa043fe894",
    "indications": {
        "text": "drospirenone , ethinyl estradiol levomefolate calcium tablet levomefolate calcium tablet combination drospirenone , progestin ethinyl estradiol , estrogen containing folate , indicated females reproductive potential : prevent pregnancy . ( 1.1 ) treat symptoms premenstrual dysphoric disorder ( pmdd ) females reproductive potential choose oral contraceptive contraception . ( 1.2 ) treat moderate acne females reproductive potential least 14 years old patient desires oral contraceptive birth control . ( 1.3 ) raise folate levels females reproductive potential choose oral contraceptive contraception . ( 1.4 )",
        "doid_entities": [
            {
                "text": "acne (DOID:6543)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6543"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "take one tablet daily mouth time every day . ( 2.1 ) tablets must taken order directed blister . ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "drospirenone , ethinyl estradiol levomefolate calcium tablets levomefolate calcium tablets available 28 tablets blister containing 28 tablets packed pouch ( ndc 68180-894-71 ) . three pouches packaged carton ( ndc 68180-894-73 ) . blister contains 28 film-coated tablets following order : 24 pink , round shaped , biconvex film-coated tablets debossed `` lu `` one side `` j61 `` side containing 3 mg drospirenone , 0.02 mg ethinyl estradiol 0.451 mg levomefolate calcium . 4 light orange , round shaped , biconvex film-coated tablets debossed `` lu `` one side `` j62 `` side containing 0.451 mg levomefolate calcium .",
    "adverseReactions": "drospirenone , ethinyl estradiol levomefolate calcium tablet levomefolate calcium tablet contraindicated females known develop following conditions : renal impairment adrenal insufficiency high risk arterial venous thrombotic diseases . examples include women known : smoke , age 35 [ boxed warning ( 5.1 ) ] deep vein thrombosis pulmonary embolism , past [ ( 5.1 ) ] cerebrovascular disease [ ( 5.1 ) ] coronary artery disease [ ( 5.1 ) ] thrombogenic valvular thrombogenic rhythm diseases heart ( example , subacute bacterial endocarditis valvular disease , atrial fibrillation ) [ ( 5.1 ) ] inherited acquired hypercoagulopathies [ ( 5.1 ) ] uncontrolled hypertension [ ( 5.6 ) ] diabetes mellitus vascular disease [ ( 5.8 ) ] headaches focal neurological symptoms migraine headaches without aura age 35 [ ( 5.9 ) ] undiagnosed abnormal uterine bleeding [ ( 5.10 ) ] current diagnosis , history , breast cancer , may hormone-sensitive [ ( 5.3 ) ] liver tumors , benign malignant , liver disease [ ( 5.4 ) ( 8.7 ) ] hepatitis c combinations containing ombitasvir/paritaprevir/ritonavir , without dasabuvir due potential alt elevations [ ( 5.5 ) ( 7.3 ) ] .",
    "ingredients": [],
    "organization": "Lupin Pharmaceuticals, Inc.",
    "name": "drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium",
    "effectiveTime": "20250414",
    "indications_original": "Drospirenone, ethinyl estradiol and levomefolate calcium tablet and levomefolate calcium tablet is a combination of drospirenone, a progestin and ethinyl estradiol, an estrogen containing a folate, indicated for use by females of reproductive potential to: Prevent pregnancy. (1.1) Treat symptoms of premenstrual dysphoric disorder (PMDD) for females of reproductive potential who choose to use an oral contraceptive for contraception. (1.2) Treat moderate acne for females of reproductive potential at least 14 years old only if the patient desires an oral contraceptive for birth control. (1.3) Raise folate levels in females of reproductive potential who choose to use an oral contraceptive for contraception. (1.4)",
    "contraindications_original": "Take one tablet daily by mouth at the      same time every day. ( 2.1 ) Tablets must be taken in the order      directed on the blister. ( 2.1 )",
    "warningsAndPrecautions_original": "Drospirenone, ethinyl estradiol and levomefolate calcium tablets and levomefolate calcium tablets are available in 28 tablets blister containing 28 tablets packed in a pouch (NDC 68180-894-71). Such three pouches are packaged in a carton (NDC 68180-894-73).\n                        Each blister contains 28 film-coated tablets in the following order:\n                        \n                           24 pink, round      shaped, biconvex film-coated tablets debossed with \"LU\" on one side      and \"J61\" on other side each containing 3 mg drospirenone, 0.02 mg      ethinyl estradiol and 0.451 mg levomefolate calcium.\n                           4 light      orange, round shaped, biconvex film-coated tablets debossed with \"LU\"      on one side and \"J62\" on other side each containing 0.451 mg      levomefolate calcium.",
    "adverseReactions_original": "Drospirenone, ethinyl estradiol and levomefolate calcium tablet and levomefolate calcium tablet is contraindicated in females who are known to have or develop the following conditions:\n                  \n                     Renal impairment\n                     Adrenal insufficiency\n                     A high risk of arterial or venous      thrombotic diseases. Examples include women who are known to:\n                           Smoke, if over age 35 [see Boxed      Warning and Warnings And Precautions (5.1)]\n                           \n                           Have deep vein thrombosis or pulmonary      embolism, now or in the past [see Warnings And Precautions (5.1)]\n                           \n                           Have cerebrovascular disease[see      Warnings And Precautions (5.1)]\n                           \n                           Have coronary artery disease[see      Warnings And Precautions (5.1)]\n                           \n                           Have thrombogenic valvular or      thrombogenic rhythm diseases of the heart (for example, subacute bacterial      endocarditis with valvular disease, or atrial fibrillation) [see      Warnings And Precautions (5.1)]\n                           \n                           Have inherited or acquired      hypercoagulopathies [see Warnings And Precautions (5.1)]\n                           \n                           Have uncontrolled hypertension [see      Warnings And Precautions (5.6)]\n                           \n                           Have diabetes mellitus with vascular      disease [see Warnings And Precautions (5.8)]\n                           \n                           Have headaches with focal neurological      symptoms or have migraine headaches with or without aura if over age 35 [see      Warnings And Precautions (5.9)]\n                           \n                        \n                     \n                     Undiagnosed abnormal uterine bleeding [see      Warnings And Precautions (5.10)]\n                     \n                     Current diagnosis of, or history of,      breast cancer, which may be hormone-sensitive [see Warnings And      Precautions (5.3)]\n                     \n                     Liver tumors, benign or malignant, or      liver disease [see Warnings And Precautions (5.4)      and Use In Specific Populations (8.7)]\n                     \n                     Use of Hepatitis C drug combinations      containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir      due to the potential for ALT elevations [see Warnings And Precautions (5.5)      and Drug Interactions (7.3)].",
    "drug": [
        {
            "name": "drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50838"
        }
    ]
}